Search
MEM 1003
go.drugbank.com/drugs/DB05547InvestigationalMEM 10003 was under investigation in clinical trial NCT00257673 (Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease) for the treatment of Alzheimer's Disease
Indoramin
go.drugbank.com/drugs/DB08950ApprovedWithdrawnIndoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese.
SAR445136
go.drugbank.com/drugs/DB17708Investigational[A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148] … It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous
MVC-COV1901
go.drugbank.com/drugs/DB15854InvestigationalThe vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210).
Flufenamic acid
go.drugbank.com/drugs/DB02266Approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Rotenone
go.drugbank.com/drugs/DB11457ExperimentalVet approvedRotenone is an isoflavone compound that naturally occurs in the jicama vine plant as well as many Fabaceae plants. It has broad spectrum insecticide and pesticide activity and is also toxic to fish.
Talsupram
go.drugbank.com/drugs/DB09191ExperimentalIt was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].
TOP-1288
go.drugbank.com/drugs/DB14839InvestigationalTOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)
V590
go.drugbank.com/drugs/DB16437ExperimentalMerck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786). … The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578].